Dr Warwick Tong is a NZ trained physician with more than 25 years of experience in the pharmaceutical and biotechnology industry.
After his early career in general medical practice, Dr Tong has held a wide variety of roles in the pharmaceutical and biotech industry in NZ (Glaxo) Singapore (GlaxoWellcome) London, Boston (Surface Logix) and Melbourne (CTx - Cancer Therapeutics CRC). His roles have included medical director, regional business development director (Asia Pacific), commercial strategy director (International) and senior vice president of development (USA).
Dr Tong was the chief executive and director of CTx from 2011 until April 2018 and chair of the CTx commercialisation company CTxONE. He was also chair of BioMedVic between May 2018 and December 2019.
Dr Tong is a member of the governance board of the ARC CoE in Convergent Bio Nano Science; a member of the SAB of the Maurice Wilkins Centre in Auckland NZ; the advisory board of Cortex Health, Melbourne; member of the industry advisory board at the School of Biomedical Sciences, University of Melbourne; and a member of the CSIRO Manufacturing Business Advisory Committee.
